Therapeutic options in acute severe ulcerative colitis

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 3, 2008, Pages 357-370

  Hare, Nicola C ^a   Arnott, Ian D R ^a   Satsangi, Jack ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Anti TNF; Biological agent; Ciclosporin; Infection; Infliximab; Malignancy; Neuropathy; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CREATININE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; LENERCEPT; MERCAPTOPURINE; MESALAZINE; PLACEBO; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VISILIZUMAB;

ABDOMINAL CANCER; ABDOMINAL CARCINOMATOSIS; ABDOMINAL DISCOMFORT; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBODY PRODUCTION; ARTHRALGIA; BASAL CELL CARCINOMA; BREAST CANCER; CANDIDIASIS; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL TRIAL; COLON DISEASE; COLON DYSPLASIA; COLON RESECTION; COMBINATION CHEMOTHERAPY; CONDUCTION BLOCK SYNDROME; CREATININE BLOOD LEVEL; CROHN DISEASE; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DISEASE SEVERITY; DIZZINESS; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED MEDICINE; FLUSHING; GASTROENTERITIS; GINGIVA HYPERPLASIA; HEART FAILURE; HERPES ZOSTER; HIRSUTISM; HISTOPLASMOSIS PNEUMONIA; HODGKIN DISEASE; HUMAN; HYPERKALEMIA; HYPERTENSION; INFECTION; INFECTIOUS COMPLICATION; INJECTION SITE IRRITATION; INJECTION SITE REACTION; KIDNEY CARCINOMA; KIDNEY FAILURE; LETHARGY; LEUKAPHERESIS; LOW BACK PAIN; LOW DRUG DOSE; LUNG CANCER; LYMPHOMA; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYALGIA; NATURAL KILLER CELL LYMPHOMA; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PARESTHESIA; PNEUMONIA; PROSTATE CANCER; PRURITUS; RECTUM CARCINOMA; REMISSION; REVIEW; SEIZURE; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; SYSTEMIC DISEASE; T CELL LYMPHOMA; THORAX PAIN; TREATMENT DURATION; TREMOR; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VASCULITIS;

ACUTE DISEASE; COLITIS, ULCERATIVE; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 55349124923     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.3.357     Document Type: Review

References (120)

1. Rubin GP, Hungin APS, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment. Pharm. Ther. 14(12), 1553-1559 (2000).
2. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126(6), 1504-1517 (2004).
3. Holtmann M, Krummenauer F, Claas C et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig. Dis. Sci. 51(9), 1516-1524 (2006).
4. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porto G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependant ulcerative colitis. Gut 55(1), 47-53 (2006).
5. Leung Y, Panaccione R, Hemmelgarn B, Jones J. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig. Dis. Sci. 53(6), 1455-1461 (2008).
6. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin. Pharmacokinet. 46(3), 187-208 (2007).
7. Kandiel A, Fraser AG, Korelitz BI, Breusinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54(8), 1121-1125 (2005).
8. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107(1), 3-11 (1994).
9. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ 2(4947), 1041-1048 (1955).
10. Carbonnel F, Gargouri D, Lemann M et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment. Pharmacol. Ther. 14(3), 273-279 (2000).
11. Chakravarty BJ. Predictors and the rate of medical treatment failure in ulcerative colitis. Am. J. Gastroenterol. 88(6), 852-855 (1993).
12. Truelove SC, Lee E, Willoughby CP, Kettlewell MGW. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 312(8099), 1086-1088 (1978).
13. Travis SP, Farrant JM, Ricketts C et al. Predicting outcome in severe ulcerative colitis. Gut 38(6), 905-910 (1996).
14. Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 10(10), 831-836 (1998).
15. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121(2), 255-260 (2001).
16. Ho GT, Chiam P, Drummond H, Loane J, Arnott IDR, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment. Pharm. Ther. 24(2), 319-330 (2006).
17. Ho GT, Mowat C, Goddard CJR et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery: Aliment. Pharm. Ther. 19(10), 1079-1087 (2004).
18. Kaplan GG, McCarthy EP, Ayanian JZ, Korzenick J, Hodin R, Sands BE. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 134(3), 680-687 (2008).
19. Hoie O, Wolters FL, Riis L et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 132(2), 507-515 (2007).
20. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. Dig. Dis. Sci. 38(6), 1137-1146 (1993).
21. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 103(5), 1444-1451 (1992).
22. Lasson DW, Pemberton JH. Current concepts and controversies in surgery for IBD. Gastroenterology 126(6), 1611-1619 (2004).
23. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 4(4), 299-308 (1963).
24. Roberts SE, Williams JG, Yeates D, Goldacre MJ. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ 335(7628), 1033(2007).
25. Fazio VW, Ziv Y, Church JM et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann. Surg. 222(2), 120-127 (1995).
26. Nieuwenhuijzen M, Reijnen MMPJ, Kuljpers JHC, Van Goor H. Small bowel obstruction after total or subtotal colectomy: a 10-year retrospective review. Br. J. Surg. 85(9), 1242-1245 (1998).
27. Bach SP, Mortensen NJ. Ileal pouch surgery for ulcerative colitis. World J. Gastroenterol. 13(24), 3288-3300 (2007).
28. Delaney CP, Fazio VW, Remzi FH et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann. Surg. 238(2), 221-228 (2003).
29. Ferrante M, Dederk S, De Hertogh G et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm. Bowel Dis. 14(1), 20-28 (2008).
30. Hahnloser D, Pemberton JH, Wolff BG, Larson DR, Crownhart BS, Dozois RR. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br. J. Surg. 94(3), 333-340 (2007).
31. Lichtenstein G, Cohen R, Yamashita B, Diamond RH. Quality of life after proctocolectomy with ileoanal anastamosis for patients with ulcerative colitis. J. Clin. Gastroenterol. 40(8), 669-677 (2006).
32. Berndtsson I, Lindholm E, Öresland T, Börjesson L. Long-term outcome after ileal pouch-anal anastamosis: function and health-related quality of life. Dis. Colon Rectum 50(10), 1545-1552 (2007).
33. Pardi DS, Sandborn WJ. Systematic review: the management of pouchitis. Aliment. Pharm. Ther. 23(8), 1087-1096 (2006).
34. Waljee A, Waljee J, Morris AM, Higgins PDR. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 55(11), 1575-1580 (2006).
35. Cornish J, Tan E, Teare J et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis. Colon Rectum 50(8), 1128-1138 (2007).
36. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330(26), 1841-1845 (1994).
37. D'Haens G, Lemmens L, Geboes K et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120(6), 1323-1329 (200l).
38. Actis G, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol. 7(1), 13 (2007).
39. Arts JM, D'Haens GM, Zeegers MM et al. Long-term outcome of treatment with intravenous cyclospotin in patients with severe ulcerative colitis. Inflamm. Bowel Dis. 10(2), 73-78 (2004).
40. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur. J. Gastroenterol. Hepatol. 17(1), 79-84 (2005).
41. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am. J. Gastroenterol. 94(6), 1587-1592 (1999).
42. Van Assche G, D'Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125(4), 1025-1031 (2003).
43. Hyde G, Jewell D, Kettlewell M, Mortensen C. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis. Colon Rectum 44(10), 1436-1440 (2001).
44. Pinna-Pintor M, Arese P, Bona R et al. Severe steroid-unresponsive ulcerative colitis. Dis. Colon Rectum 43(5), 609-613 (2000).
45. Moskovitz DN, Van Assche G, Maenhout B et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 4(6), 760-765 (2006).
46. Shibolet O, Regnshevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst. Rev. 1, CD004277 (2005).
47. Sands BE. Biologic therapy for inflammatory bowel disease. Inflamm. Bowel Dis. 3(2), 95-113 (1997).
48. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNFα monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7(3), 251-259 (1995).
49. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121(5), 1145-1157 (2001).
50. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50(2), 206-211 (2002).
51. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor α blocking agents for induction and remission in ulcerative colitis. Cochrane Database Syst. Rev. 3, CD005112 (2006).
52. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002).
53. Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin. Gastroenterol. Hepatol. 2(10), 912-920 (2004).
54. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350(9), 876-885 (2004).
55. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005).
56. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317(26), 1625-1629 (1987).
57. Feagan BG, Reinisch W, Rutgeerts P et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am. J. Gastroenterol. 102(4), 794-802 (2007).
58. Reinisch W, Sandborn WJ, Bala M et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity in patients with ulcerative colitis. Inflam. Bowel Dis. 13(9), 1135-1140 (2007).
59. Gisbert JR Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment. Pharm. Ther. 25(1), 19-37 (2007).
60. Jarnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128(7), 1805-1811 (2005).
61. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am. J. Gastroenterol. 87(8), 971-976 (1992).
62. Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 10(10), 831-836 (1998).
63. Jakobovits SL, Jewell DP, Travis SPL. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment. Pharm. Ther. 25(9), 1055-1060 (2007).
64. Lees CW, Heys D, Ho GT et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment. Pharm. Ther. 26(3), 411-419 (2007).
65. Kohn A, Daperno M, Armuzzi A et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment. Pharm. Ther. 26(5), 747-756 (2007).
66. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348(7), 601-608 (2003).
67. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124(4), 917-924 (2003).
68. Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest. Endosc. 63(3), 433-442 (2006).
69. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2(7), 542-553 (2004).
70. Parsi MA, Achkar JP, Richardson S et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123(3), 707-713 (2002).
71. Arnott IDR, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment. Pharm. Ther. 17(12), 1451-1457 (2003).
72. Mortimore M, Gibson PR, Selby WS et al. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-α, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern. Med. J. 31(3), 146-150 (2001).
73. Laharie D, Salzmann M, Boubekeur H et al. Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol. Clin. Biol. 29(2), 145-149 (2005).
74. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 13(7), 933-934 (2007).
75. Toruner M, Loftus EV, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatoty bowel disease. Gastroenterology 134(4), 929-936 (2008).
76. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19), 2275-2285 (2006).
77. Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin. Drug Saf. 5(1), 9-16 (2006).
78. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infectious associated with the inhibition of tumor necrosis factor. Nat. Clin. Prac. Rhuematol. 2(11), 602-610 (2006).
79. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38(9), 1261-1265 (2004).
80. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-α treatment of inflammatory bowel disease. Aliment. Pharm. Ther. 27(1), 19-30 (2008).
81. Colombel JF, Loftus EV, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 126(1), 19-31 (2004).
82. Sachmechian A, Vasillauskas EA, Abreu MT et al. Malignancy following Remicade™ therapy: incidence and characteristics. Gastroenterology 120(5 Suppl. 1), A619 (2001).
83. Melichar B, Buses J, Dedic K. Anorectal carcinoma after infliximab therapy in Crohn's disease: report of a case. Dis. Colon Rectum 49(8), 1228-1233 (2006).
84. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002).
85. Lichtenstein GR, Cohen RD, Feagan BG et al. Safety of infliximab and other Crohn's disease therapies: updated TREAT registry data with over 10,000 patient-yeass of follow-up (abstract). Gastroenterology 128(4 Suppl. 2), A580 (2005).
86. Biancone L, Calabrese L, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 4(2), 78-91 (2007).
87. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with inflixiamb use in young patients treated for inflammatory bowel dase. J. Pediatr. Gastroenterol. Nutr. 44(2), 265-267 (2007).
88. Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 56(9), 1181-1183 (2007).
89. Rennard SI, Fogany C, Kelsen S et al. The safety and efficacy of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175(9), 926-934 (2007).
90. Askling J, Fored M, Baecklund E et al. Hematopoietic malignancies in rheumatoid arthritis. Lymphoma risk and charccteristics following TNFα antagonists. Ann. Rheum. Dis. 64(10), 1414-11420 (2005).
91. Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin. Exp. Rheumatol. 22(5 Suppl. 35), S134-S140 (2004).
92. Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum. 44(12), 2862-2869 (2001).
93. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53(3), 457-465 (1999).
94. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 129(3), 819-826 (2005).
95. Hansen RA, Gartlehner G, Powell GE, Sandier RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin. Gastroenterol. Hepatol. 5(6), 729-735 (2007).
96. Curds JR, Kramer JM, Martin C et al. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNFα antagonists. Rheumatology 46(11), 1688-1693 (2007).
97. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) Trial. Circulation 107(25), 3133-3140 (2003).
98. Schluender SJ, Ippoliti A, Dubinsky M et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastamosis in patients with ulcerative colitis? Dis. Colon Rectum 50(11), 1747-1753 (2007).
99. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J. Immunol. 151 (7), 3460-3466 (1993).
100. Creed TJ, Norman MR, Probert CSJ et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment. Pharm. Ther. 18(1), 65-75 (2003).
101. Creed TJ, Prober CSJ, Norman MN et al. Basiliximab for the treatment of steroid resistant ulcerative colitis: further experience in moderate and severe disease. Aliment. Pharm. Ther. 23(10), 1435-1442 (2006).
102. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 326(7393), 789 (2003).
103. Carpenter PA, Pavlovic S, Tso JY et al. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J. Immunol. 165(11), 6205-6213 (2000).
104. Plevy S, Salzberg B, Van Assche G et al. A Phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133(5), 1414-1422 (2007).
105. Carpenter PA, Sanders JE. Steroid-refractory graft-vs.-host disease: past, present and future. Pediatr. Transplant. 7(Suppl. 3), 19-31 (2003).
106. Kino T, Hatanaka H, Myata S et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antiobiot. (Tokyo) 40(9) 1256-1265 (1987).
107. Kelly PA, Busckart GJ, Venkataramanan R. Tacrolimus: a new immunosuppressive agent. Am. J. Health Syst. Pharm. 52(14), 1569-1571 (1995).
108. Kino T, Hatanaka H, Hashimoto M et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antiobiot. (Tokyo) 40(9) 1249-1255 (1987).
109. Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowd disease: immunomodulation by tacrolimus (FK506). Am. J. Gastroenterol. 93(10), 1860-1866 (1998).
110. Fellermann K, Tanko Z, Herrliner KR et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflam. Bowel Dis. 8(5), 317-324 (2002).
111. Högenauer C, Weuzl H, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK506) on steroid-refractory rnoderate/severe ulcerative colitis. Aliment. Pharm. Ther. 18(4), 415-423 (2003).
112. Baumgert DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment. Pharm. Ther. 17(10), 1273-1281 (2003).
113. Baumgert DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependant inflammatory bowel disease - a long-term follow-up. Am. J. Gastroenterol. 101(5), 1048-1056 (2006).
114. Ogata H, Matsui T, Nakamura M et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55(9), 1255-1262 (2006).
115. Sawada K, Kususgami K, Suzuki Y et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol. 100(6), 1362-1369 (2005).
116. Sawada K, Muto T, Shimoyama T et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr. Pharm. Des. 9(4), 307-321 (2003).
117. Nishioka C, Aoyama N, Maekawa S et al. Leukocytapheresis therapy for steroid-naive patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J. Gastroenterol. Hepatol. 20(10), 1567-1571 (2005).
118. Honma T, Sugimura K, Asakura H et al. Leukocytapheresis is effective in inducing but not maintaining remission in ulcerative colitis. J. Clin. Gastroenterol. 39(10), 886-890 (2005).
119. Shimoyama T, Sawada K, Hiwatashi N et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with ulcerative colitis: a multicentre study. J. Clin. Apher. 16(1), 1-9 (2001).
120. Hanai H, Watanabe F, Takeuchi K et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin. Gastroenterol. Hepatol. 1(1), 28-35 (2003).